Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell activation via co-stimulation is a crucial process for initiating adaptive immune responses. It involves the interaction of co-stimulatory molecules on antigen-presenting cells (APCs) with their receptors on T cells, providing a second signal alongside TCR engagement. This ensures full T cell activation, proliferation, differentiation, and survival, while its absence leads to anergy, apoptosis, or tolerance. Key co-stimulatory molecules include CD28, OX40, and 4-1BB, while inhibitory receptors like CTLA4 and PD-1 regulate the process. Targeting these pathways is a major focus in immunotherapy for cancer, autoimmunity, and transplantation.
Modulation of T cell activation through agonism or antagonism of co-stimulatory or co-inhibitory receptors, altering downstream signaling pathways affecting T cell function.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell activation (co-stimulation-mediated) (N/A).